SECOND BRAZILIAN CONSENSUS ON THE MANAGEMENT OF CROHN’S DISEASE IN ADULTS: A CONSENSUS OF THE BRAZILIAN ORGANIZATION FOR CROHN’S DISEASE AND COLITIS (GEDIIB)
Abstract Background: Inflammatory bowel disease (IBD) is an immune-mediated disorder that includes Crohn’s disease (CD) and ulcerative colitis. CD is characterized by a transmural intestinal involvement from the mouth to the anus with recurrent and remitting symptoms that can lead to progressive bowel damage and disability over time. Objective: To guide the safest and effective […]
Can Proactive Therapeutic Drug Monitoring Overcome Pharmacogenomic-Associated Immunogenicity to Anti-Tumor Necrosis Factor Agents?
Letter to editor Antidrug antibody (ADA) formation, so-called immunogenicity, is a major issue when using anti–tumor necrosis factor (anti-TNF) therapy to treat patients with immune-mediated inflammatory diseases because it can lead to treatment failure and drug discontinuation. 1 Increasing evidence suggests that pharmacogenomics may help in identifying patients who are more prone to develop ADA […]